Paradigm Biopharmaceuticals (ASX:PAR) chief executive officer, Paul Rennie, is a major shareholder in the company and on-market purchases have lifted him to a 22.06% stake.
Earlier in the week Rennie spent just over $100,000 acquiring more shares.
The next steps for Paradigm will be to focus on completing the Phase 2 Bone Marrow Edema clinical trial and commencing the Ross River clinical trial.